These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 10960070)

  • 1. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species.
    Ugawa T; Kakuta H; Moritani H; Matsuda K; Ishihara T; Yamaguchi M; Naganuma S; Iizumi Y; Shikama H
    Br J Pharmacol; 2000 Sep; 131(1):63-70. PubMed ID: 10960070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model.
    Ugawa T; Kakuta H; Moritani H; Shikama H
    Br J Pharmacol; 2002 Mar; 135(6):1572-8. PubMed ID: 11906972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents.
    Ugawa T; Kakuta H; Moritani H; Inagaki O; Shikama H
    Br J Pharmacol; 2003 May; 139(1):140-6. PubMed ID: 12746232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of YM-53601, a novel squalene synthase inhibitor, on the clearance rate of plasma LDL and VLDL in hamsters.
    Ugawa T; Kakuta H; Moritani H; Inagaki O
    Br J Pharmacol; 2002 Oct; 137(4):561-9. PubMed ID: 12359639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Syntheses of 3-ethylidenequinuclidine derivatives as squalene synthase inhibitors. Part 2: enzyme inhibition and effects on plasma lipid levels.
    Ishihara T; Kakuta H; Moritani H; Ugawa T; Sakamoto S; Tsukamoto Si; Yanagisawa I
    Bioorg Med Chem; 2003 Aug; 11(17):3735-45. PubMed ID: 12901918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro.
    Nishimoto T; Amano Y; Tozawa R; Ishikawa E; Imura Y; Yukimasa H; Sugiyama Y
    Br J Pharmacol; 2003 Jul; 139(5):911-8. PubMed ID: 12839864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.
    Amin D; Rutledge RZ; Needle SN; Galczenski HF; Neuenschwander K; Scotese AC; Maguire MP; Bush RC; Hele DJ; Bilder GE; Perrone MH
    J Pharmacol Exp Ther; 1997 May; 281(2):746-52. PubMed ID: 9152381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism.
    Hiyoshi H; Yanagimachi M; Ito M; Saeki T; Yoshida I; Okada T; Ikuta H; Shinmyo D; Tanaka K; Kurusu N; Tanaka H
    Eur J Pharmacol; 2001 Nov; 431(3):345-52. PubMed ID: 11730728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of novel propylamine derivatives as orally active squalene synthase inhibitors.
    Ishihara T; Kakuta H; Moritani H; Ugawa T; Yanagisawa I
    Bioorg Med Chem; 2004 Nov; 12(22):5899-908. PubMed ID: 15498666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
    Flint OP; Masters BA; Gregg RE; Durham SK
    Toxicol Appl Pharmacol; 1997 Jul; 145(1):91-8. PubMed ID: 9221828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia.
    Amano Y; Nishimoto T; Tozawa Ri; Ishikawa E; Imura Y; Sugiyama Y
    Eur J Pharmacol; 2003 Apr; 466(1-2):155-61. PubMed ID: 12679152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-coa reductase inhibitors.
    Hiyoshi H; Yanagimachi M; Ito M; Ohtsuka I; Yoshida I; Saeki T; Tanaka H
    J Lipid Res; 2000 Jul; 41(7):1136-44. PubMed ID: 10884296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway.
    Do R; Kiss RS; Gaudet D; Engert JC
    Clin Genet; 2009 Jan; 75(1):19-29. PubMed ID: 19054015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
    Aoki T; Nishimura H; Nakagawa S; Kojima J; Suzuki H; Tamaki T; Wada Y; Yokoo N; Sato F; Kimata H; Kitahara M; Toyoda K; Sakashita M; Saito Y
    Arzneimittelforschung; 1997 Aug; 47(8):904-9. PubMed ID: 9296275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting cellular squalene synthase, an enzyme essential for cholesterol biosynthesis, is a potential antiviral strategy against hepatitis C virus.
    Saito K; Shirasago Y; Suzuki T; Aizaki H; Hanada K; Wakita T; Nishijima M; Fukasawa M
    J Virol; 2015 Feb; 89(4):2220-32. PubMed ID: 25473062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs.
    Nishimoto T; Ishikawa E; Anayama H; Hamajyo H; Nagai H; Hirakata M; Tozawa R
    Toxicol Appl Pharmacol; 2007 Aug; 223(1):39-45. PubMed ID: 17599378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Syntheses and biological evaluation of novel quinuclidine derivatives as squalene synthase inhibitors.
    Ishihara T; Kakuta H; Moritani H; Ugawa T; Sakamoto S; Tsukamoto S; Yanagisawa I
    Bioorg Med Chem; 2003 May; 11(11):2403-14. PubMed ID: 12735986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A high-cholesterol, n-3 polyunsaturated fatty acid diet causes different responses in rats and hamsters.
    Lin MH; Lu SC; Huang PC; Liu YC; Liu SY
    Ann Nutr Metab; 2005; 49(6):386-91. PubMed ID: 16219990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
    Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unrefined and refined black raspberry seed oils significantly lower triglycerides and moderately affect cholesterol metabolism in male Syrian hamsters.
    Ash MM; Wolford KA; Carden TJ; Hwang KT; Carr TP
    J Med Food; 2011 Sep; 14(9):1032-8. PubMed ID: 21548801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.